Skip to content

Effect of High-flow Nasal Cannula in High Carbon Dioxide Patients

High-flow Nasal Cannula in Non-severe Hypercapnia: a Prospective Multicenter Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0003448
Enrollment
100
Registered
2019-01-25
Start date
2017-11-25
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : High-flow nasal cannula

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients in the emergency room or admitted to the hospital who have non-severe hypercapnia which is defined as partial pressure of arterial carbon dioxide of 43 - 69 mmHg and PH above 7.3 by arterial blood gas.

Exclusion criteria

Exclusion criteria: 1. Patients with any sign of imminent respiratory failure requiring intubation and mechanical ventilation 2. Patients with unstable hemodynamics (systolic blood pressure less than 100 mmHg, mean blood pressure less than 60 mmHg, or heart rate faster than 120 beats per minute 3. Patients with shock, intractable arrhythmia, post-CPR status, or ECMO 4. Patients with consciousness disorder which would require intubation (e.g., not responsive, agitated, uncooperative, high risk for aspiration) 5. Patients who had facial surgery, trauma or deformity and airway obstruction that precludes application of nasal cannula.

Design outcomes

Primary

MeasureTime frame
Partial pressure of carbon dioxide

Secondary

MeasureTime frame
Number of patients who were discontinued from HFNC according to the treatment failure criteria and the changes in vital signs and other parameters in ABGA

Countries

Korea, Republic of

Contacts

Public ContactKyung Hun Nam

Asan Medical Center

nambakk@hotmail.com+82-2-3010-4700

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026